These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25384907)

  • 21. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa.
    Musinguzi N; Muganzi CD; Boum Y; Ronald A; Marzinke MA; Hendrix CW; Celum C; Baeten JM; Bangsberg DR; Haberer JE;
    AIDS; 2016 Apr; 30(7):1121-9. PubMed ID: 26785125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender Women.
    Sheth AN; Momplaisir F; Dumond JB
    JAMA; 2024 Mar; 331(11):912-914. PubMed ID: 38427361
    [No Abstract]   [Full Text] [Related]  

  • 23. Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation.
    Chakrapani V; Newman PA; Shunmugam M; Mengle S; Varghese J; Nelson R; Bharat S
    AIDS Patient Care STDS; 2015 Oct; 29(10):569-77. PubMed ID: 26348459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials.
    Amico KR; Mansoor LE; Corneli A; Torjesen K; van der Straten A
    AIDS Behav; 2013 Jul; 17(6):2143-55. PubMed ID: 23435697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017.
    Balán IC; Giguere R; Brown W; Carballo-Diéguez A; Horn S; Hendrix CW; Marzinke MA; Ayudhya RPKN; Patterson K; Piper JM; McGowan I; Lama JR; Cranston RD;
    AIDS Behav; 2018 Mar; 22(3):986-995. PubMed ID: 29076032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.
    Stoner MCD; Browne EN; Gundacker HM; Hawley I; Chen BA; Hoesley C; Scheckter R; Piper J; Singh D; Song M; Liu A; van der Straten A
    PLoS One; 2022; 17(2):e0263664. PubMed ID: 35192655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Policy and practice, lost in transition: Reasons for high drop-out from pre-antiretroviral care in a resource-poor setting of eastern Uganda.
    Lubega M; Nsabagasani X; Tumwesigye NM; Wabwire-Mangen F; Ekström AM; Pariyo G; Peterson S
    Health Policy; 2010 May; 95(2-3):153-8. PubMed ID: 20022131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of pre-exposure prophylaxis adherence to a mental health diagnosis or experience of childhood trauma in high-risk youth.
    Young LB; Lalley-Chareczko L; Clark D; Ramos MT; Nahan RA; Troutman GS; Cantor R; DiFlavis L; Koenig HC
    Int J STD AIDS; 2020 Apr; 31(5):440-446. PubMed ID: 32208815
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
    Friend DR; Kiser PF
    Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP.
    Blumenthal J; Jain S; Krakower D; Sun X; Young J; Mayer K; Haubrich R;
    AIDS Behav; 2015 May; 19(5):802-10. PubMed ID: 25616837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis Among Adolescent Girls.
    Baker Z; Javanbakht M; Moore J; Brosnan H; Squires K; Bunge K; Zimet G; Mensch B; Soto-Torres L; Kapogiannis B; Levy L; Hoesley C; Reirden D; Gaur A; Mayer K; Futterman D; Gorbach P
    J Acquir Immune Defic Syndr; 2021 Jul; 87(3):944-950. PubMed ID: 33675614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influences on visit retention in clinical trials: insights from qualitative research during the VOICE trial in Johannesburg, South Africa.
    Magazi B; Stadler J; Delany-Moretlwe S; Montgomery E; Mathebula F; Hartmann M; van der Straten A
    BMC Womens Health; 2014 Jul; 14():88. PubMed ID: 25065834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acceptability of PrEP for HIV prevention among women at high risk for HIV.
    Guest G; Shattuck D; Johnson L; Akumatey B; Clarke EE; Chen PL; Macqueen KM
    J Womens Health (Larchmt); 2010 Apr; 19(4):791-8. PubMed ID: 20210540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe.
    Musara P; Montgomery ET; Mgodi NM; Woeber K; Akello CA; Hartmann M; Cheng H; Levy L; Katz A; Grossman CI; Chirenje ZM; van der Straten A; Mensch B;
    AIDS Behav; 2018 Mar; 22(3):877-886. PubMed ID: 28110473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.
    Montgomery ET; Stadler J; Naidoo S; Katz AWK; Laborde N; Garcia M; Reddy K; Mansoor LE; Etima J; Zimba C; Chitukuta M; Soto-Torres L
    AIDS; 2018 Jul; 32(11):1517-1525. PubMed ID: 29957723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing adherence in HIV prevention product trials: Development and psychometric evaluation of simple tools for screening and adherence counseling.
    Tolley EE; Guthrie KM; Zissette S; Fava JL; Gill K; Louw CE; Kotze P; Reddy K; MacQueen K
    PLoS One; 2018; 13(4):e0195499. PubMed ID: 29649249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Culturally-Based Challenges to and Recommendations for Delivering Adherence Counseling in a Multicultural Biomedical HIV Prevention Trial in Four African Countries.
    Lentz C; Giguere R; Kutner BA; Dolezal C; Kajura-Manyindo C; Yambira M; Asiimwe F; Mugocha C; Mwenda W; Ndlovu T; Naidu N; Madlala B; Balán IC
    AIDS Educ Prev; 2020 Dec; 32(6):512-527. PubMed ID: 33779210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design.
    Guthrie KM; Dunsiger S; Vargas SE; Fava JL; Shaw JG; Rosen RK; Kiser PF; Kojic EM; Friend DR; Katz DF
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1022-1030. PubMed ID: 26942455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Counselors' acceptability of adherence counseling session recording, fidelity monitoring, and feedback in a multi-site HIV prevention study in four African countries.
    Giguere R; Lentz C; Kajura-Manyindo C; Kutner BA; Dolezal C; Buthelezi M; Lukas I; Nampiira S; Rushwaya C; Sitima E; Katz A; van der Straten A; Balán IC
    AIDS Care; 2020; 32(sup1):19-28. PubMed ID: 33021118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementation of a fidelity monitoring process to assess delivery of an evidence-based adherence counseling intervention in a multi-site biomedical HIV prevention study.
    Balán IC; Lentz C; Giguere R; Mayo AJ; Rael CT; Soto-Torres L; Palanee-Phillips T; Mgodi NM; Hillier S; Baeten JM;
    AIDS Care; 2020 Sep; 32(9):1082-1091. PubMed ID: 31899954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.